Segmented results for the year ended 31 December 2017
| Pipeline R&D | Commercial | Consolidated | ||||||||||
| £’000 | £’000 | £’000 | ||||||||||
| Revenue | 108 | 6,650 | 6,758 | |||||||||
| Grant revenue | 840 | - | 840 | |||||||||
| Total revenue | 948 | 6,650 | 7,598 | |||||||||
| Cost of sales | - | (926 | ) | (926 | ) | |||||||
| Research and development costs | (9,830 | ) | (355 | ) | (10,185 | ) | ||||||
| Distribution
costs, sales and marketing |
(744 | ) | (7,096 | ) | (7,840 | ) | ||||||
| Administrative costs | (1,685 | ) | (480 | ) | (2,165 | ) | ||||||
| Depreciation | (974 | ) | (9 | ) | (983 | ) | ||||||
| Amortisation | (193 | ) | (1,384 | ) | (1,577 | ) | ||||||
| Impairment | (1,500 | ) | - | (1,500 | ) | |||||||
| Loss from operations | (13,978 | ) | (3,600 | ) | (17,578 | ) | ||||||
| Finance income | 415 | |||||||||||
| Finance expense | (166 | ) | ||||||||||
| Loss before tax | (17,329 | ) | ||||||||||
| Taxation | 1,265 | |||||||||||
| Loss for the year | (16,064 | ) | ||||||||||
Segmented results for the year ended 31 December 2016
| Pipeline R&D | Commercial | Consolidated | ||||||||||
| £’000 | £’000 | £’000 | ||||||||||
| Revenue | 776 | 5,600 | 6,376 | |||||||||
| Grant revenue | 547 | - | 547 | |||||||||
| Total revenue | 1,323 | 5,600 | 6,923 | |||||||||
| Cost of sales | (9 | ) | (658 | ) | (667 | ) | ||||||
| Research
and development costs (reclassified) |
(7,786 | ) | (10 | ) | (7,796 | ) | ||||||
| Distribution
costs, sales and marketing (reclassified) |
(396 | ) | (8,531 | ) | (8,927 | ) | ||||||
| Administrative costs (reclassified) | (2,279 | ) | (2,072 | ) | (4,351 | ) | ||||||
| Depreciation | (762 | ) | (10 | ) | (772 | ) | ||||||
| Amortisation | (193 | ) | (3,390 | ) | (3,583 | ) | ||||||
| Impairment | - | (11,413 | ) | (11,413 | ) | |||||||
| Loss from operations | (10,102 | ) | (20,484 | ) | (30,586 | ) | ||||||
| Finance income | 1,337 | |||||||||||
| Finance expense | (73 | ) | ||||||||||
| Loss before tax | (29,322 | ) | ||||||||||
| Taxation | 9,160 | |||||||||||
| Loss for the year | (20,162 | ) | ||||||||||
Segmented results for the year ended 31 December 2015
| Pipeline R&D | Commercial | Unallocated Costs(1) |
Consolidated | |||||||||||||
| £’000 | £’000 | £’000 | £’000 | |||||||||||||
| Revenue | 273 | 502 | - | 775 | ||||||||||||
| Grant revenue | 600 | - | - | 600 | ||||||||||||
| Total revenue | 873 | 502 | - | 1,375 | ||||||||||||
| Cost of sales | - | (70 | ) | - | (70 | ) | ||||||||||
| Research
and development costs (reclassified) |
(8,601 | ) | (109 | ) | - | (8,710 | ) | |||||||||
| Distribution
costs, sales and marketing (reclassified) |
- | (369 | ) | (369 | ) | |||||||||||
| Administrative costs (reclassified) | (1,151 | ) | (265 | ) | (2,991 | ) | (4,407 | ) | ||||||||
| Depreciation | (500 | ) | (1 | ) | - | (501 | ) | |||||||||
| Amortisation | (5 | ) | (231 | ) | - | (236 | ) | |||||||||
| Loss from operations | (9,384 | ) | (543 | ) | (2,991 | ) | (12,918 | ) | ||||||||
| Finance income | 1,691 | |||||||||||||||
| Finance expense | (5 | ) | ||||||||||||||
| Loss before tax | (11,232 | ) | ||||||||||||||
| Taxation | 1,133 | |||||||||||||||
| Loss for the year | (10,099 | ) | ||||||||||||||
(1) There were no unallocated costs in 2017 or 2016. Unallocated costs in 2015 represent fees associated with the acquisitions of Midatech Pharma US, Inc. and Zuplenz® in 2015.